InVera Medical

InVera Medical is a private, clinical-stage medical device company targeting the large and underserved market for chronic venous disease (CVD) treatments. Its core innovation is the InVera Infusion Device, a catheter system that uses a unique nitinol helical coil to mechanically disrupt the vein wall and enhance the delivery of therapeutic agents, aiming for a more effective and patient-friendly alternative to existing procedures. With CE Mark approval in hand, the company is positioned for a European commercial launch, while its US regulatory pathway remains in the investigational stage, representing both a significant opportunity and a key near-term hurdle.

A proprietary catheter-based platform featuring a nitinol helical coil with a micro-textured surface designed to mechanically disrupt the vein wall, induce venospasm, and enhance the delivery and efficacy of infused therapeutic agents (e.g., sclerosants) for the treatment of superficial venous reflux.

InVera competes in the minimally invasive venous ablation market, primarily against established thermal devices (laser, radiofrequency from companies like Medtronic, Boston Scientific) and other non-thermal options like mechanochemical ablation (ClariVein) and foam sclerotherapy. Its differentiation lies in its unique mechanical wall disruption mechanism combined with chemical infusion, aiming for improved efficacy over sclerotherapy alone without the capital cost of thermal systems.